TY - JOUR
T1 - Baseline renal function and the risk of cancer among apparently healthy middle-aged adults
AU - Moshkovits, Yonatan
AU - Goldman, Adam
AU - Beckerman, Pazit
AU - Tiosano, Shmuel
AU - Kaplan, Alon
AU - Kalstein, Maia
AU - Bayshtok, Gabriella
AU - Segev, Shlomo
AU - Grossman, Ehud
AU - Segev, Amit
AU - Maor, Elad
N1 - Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/10
Y1 - 2023/10
N2 - Background: The association between mildly impaired renal function with all-site and site-specific cancer risk is not established. We aim to explore this association among apparently healthy adults. Methods: We followed 25,073 men and women, aged 40–79 years, free of cancer or cardiovascular disease at baseline who were screened annually in preventive healthcare settings. The estimated glomerular filtration rate (eGFR) was calculated using the CKD Epidemiology Collaboration equation (CKD-EPI) and classified into four mutually exclusive groups: <60, 60–74, 75–89, ≥90 (mL/min/1.73 m²). The primary outcome was all-site cancer while the secondary outcome was site-specific cancer. Cancer data was available from a national registry. Results: Mean age at baseline was 50 ± 8 years and 7973 (32 %) were women. During a median follow-up of 9 years (IQR 3–16) and 256,279 person years, 2045 (8.2 %) participants were diagnosed with cancer. Multivariable Cox model showed a 1.2 (95 %CI: 1.0–1.4 p = 0.05), 1.2 (95 %CI: 1.0–1.4 p = 0.02), and 1.4 (95 %CI: 1.1–1.7 p = 0.003) higher risk for cancer with eGFR of 75–89, 60–74, and < 60, respectively. Site-specific analysis demonstrated a 1.8 (95 %CI: 1.2–2.6 p = 0.004), 1.7 (95 %CI: 1.2–2.6 p = 0.004) and 2.2 (95 %CI: 1.3–3.6 p = 0.002) increased risk for prostate cancer with eGFR of 75–89, 60–74, and < 60, respectively. eGFR< 60 was associated with a 2.0 (95 %CI: 1.1–3.7 p = 0.03) and 3.7 (95 %CI: 1.1–13.1 p = 0.04) greater risk for melanoma and gynecological caner respectively. Conclusions: CKD stage 2 and worse is independently associated with higher risk for cancer incidence, primarily prostate cancer. Early intervention and screening are warranted among these individuals in order to reduce cancer burden.
AB - Background: The association between mildly impaired renal function with all-site and site-specific cancer risk is not established. We aim to explore this association among apparently healthy adults. Methods: We followed 25,073 men and women, aged 40–79 years, free of cancer or cardiovascular disease at baseline who were screened annually in preventive healthcare settings. The estimated glomerular filtration rate (eGFR) was calculated using the CKD Epidemiology Collaboration equation (CKD-EPI) and classified into four mutually exclusive groups: <60, 60–74, 75–89, ≥90 (mL/min/1.73 m²). The primary outcome was all-site cancer while the secondary outcome was site-specific cancer. Cancer data was available from a national registry. Results: Mean age at baseline was 50 ± 8 years and 7973 (32 %) were women. During a median follow-up of 9 years (IQR 3–16) and 256,279 person years, 2045 (8.2 %) participants were diagnosed with cancer. Multivariable Cox model showed a 1.2 (95 %CI: 1.0–1.4 p = 0.05), 1.2 (95 %CI: 1.0–1.4 p = 0.02), and 1.4 (95 %CI: 1.1–1.7 p = 0.003) higher risk for cancer with eGFR of 75–89, 60–74, and < 60, respectively. Site-specific analysis demonstrated a 1.8 (95 %CI: 1.2–2.6 p = 0.004), 1.7 (95 %CI: 1.2–2.6 p = 0.004) and 2.2 (95 %CI: 1.3–3.6 p = 0.002) increased risk for prostate cancer with eGFR of 75–89, 60–74, and < 60, respectively. eGFR< 60 was associated with a 2.0 (95 %CI: 1.1–3.7 p = 0.03) and 3.7 (95 %CI: 1.1–13.1 p = 0.04) greater risk for melanoma and gynecological caner respectively. Conclusions: CKD stage 2 and worse is independently associated with higher risk for cancer incidence, primarily prostate cancer. Early intervention and screening are warranted among these individuals in order to reduce cancer burden.
KW - Cancer
KW - Chronic kidney disease
KW - Renal function
KW - Site-specific cancer
UR - http://www.scopus.com/inward/record.url?scp=85165594338&partnerID=8YFLogxK
U2 - 10.1016/j.canep.2023.102428
DO - 10.1016/j.canep.2023.102428
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37482051
AN - SCOPUS:85165594338
SN - 1877-7821
VL - 86
JO - Cancer Epidemiology
JF - Cancer Epidemiology
M1 - 102428
ER -